Paul Rittman becomes CEO of Helsinn Therapeutics

Company: Helsinn Therapeutics

Appointee: Paul Rittman



Paul Rittman, a pharmaceutical sales and marketing executive, has been appointed chief executive of Helsinn Therapeutics, the US subsidiary of the Swiss Helsinn Group, a producer of products for cancer care. Mr Rittman replaces William Mann who stepped down on 28 February. Prior to joining Helsinn, he was general manager of US oncology for Teva Pharmaceutical Industries Ltd, overseeing the company’s branded products operation. Before that, he worked at IntraBiotics Pharmaceuticals Inc and Aventis, a predecessor company to Sanofi SA.

Helsinn announced the appointment on 27 February 2018

Copyright 2018 Evernow Publishing Ltd